Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 4 Stomach Neoplasms 1 Rare Tumour 1 Neoplasms 1 Neoadjuvant Therapy 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Locally Advanced Prostate Cancer 1 Limited Stage Small Cell Lung Cancer 1 Hereditary leiomyomatosis and renal cell cancer 1 HER2-negative Breast Cancer 1 Carcinosarcoma 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 45 Cisplatin 34 Oxaliplatin 23 Capecitabine 17 Fluorouracil 13 Leucovorin 12 pembrolizumab 11 lenvatinib 11 durvalumab 10 S 1 (combination) 10 Irinotecan 10 Bevacizumab 9 apatinib 7 Nivolumab 7 tremelimumab 6 Trastuzumab 5 envafolimab 4 atezolizumab 4 Injections 4 Docetaxel 4 trametinib 3 titanium silicide 3 tislelizumab 3 irinotecan sucrosofate 3 camrelizumab 3 Radiotherapy 3 Drug Therapy 3 zanidatamab 2 toripalimab 2 surufatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Biliary Tract Neoplasms × pamiparib × Clear all

NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡